

U.S.S.N. 09/378,261
Filed: August 20, 1999
AMENDMENT

receptor to block binding of protein C or activated protein C to the receptor by binding to the endothelial cell protein C/activated protein C receptor.

26. The method of claim [16] 24 wherein the [compound] antibody or antibody fragment is labeled.

Remarks

Claims 24 and 26 were objected to as being dependent on a rejected claim. Claim 24 has been rewritten in independent form. Claim 26 has been amended to give proper antecedant support for the proposed amendment to claim 24. Support for this amendment is found on page 19, lines 23-27 of the specification. Both claims 25 and 26 depend from claim 24, so claims 24-26 should now be allowed.

It is believed that the amendment should be entered as it places the claims in better form for appeal, reduces issues for appeal, does not raise any new issues, and does not require further consideration or search.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: March 11, 2002
HOLLAND & KNIGHT LLP
One Atlantic Center, Suite 2000
1201 West Peachtree Street
Atlanta, Georgia 30309-3400
(404) 817-8473
(404) 817-8588 (Fax)

U.S.S.N. 09/378,261
Filed: August 20, 1999

MARKED UP VERSION OF AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121



Marked Up Version of Amended Claims

Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)

16. (amended) A method for enhancing an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor comprising administering to a patient in need of treatment thereof an amount of a compound blocking binding of protein C or activated protein C to the receptor by binding to the endothelial cell protein C/activated protein C receptor.

17. (amended) The method of claim 16 wherein the compound is selected from the group consisting of antibodies and fragments of antibodies to the receptor, [nucleic acid sequences inhibiting expression of the receptor,] and synthetic or natural compounds other than proteins, or peptides [or nucleic acid sequences] which inhibit binding.

24. The method of claim 16 wherein the compound is an antibody or antibody fragment immunoreactive with the receptor.

25. The method of claim 24 wherein the antibody is humanized.

26. The method of claim 16 wherein the compound is labeled.

27. The method of claim 16 wherein the compound is an oligonucleotide.

28. The method of claim 16 wherein the compound is a receptor fragment.

29. The method of claim 16 wherein the compound is combined with a pharmaceutically acceptable carrier.

U.S.S.N. 09/378,261
Filed: August 20, 1999

MARKED UP VERSION OF AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121

30. The method of claim 16 wherein the compound is administered in an amount effective to enhance an inflammatory response involving blocking of protein C or activated protein C binding to an endothelial cell protein C/activated protein C receptor.